The quest to overcome resistance to EGFR-targeted therapies in cancer

被引：0
|
作者：
Curtis R Chong
Pasi A Jänne
机构：
[1] Lowe Center for Thoracic Oncology,Department of Medicine
[2] Dana-Farber Cancer Institute,undefined
[3] Brigham and Women's Hospital,undefined
[4] Belfer Institute for Applied Cancer Science,undefined
[5] Dana-Farber Cancer Institute,undefined
来源：
Nature Medicine | 2013年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Despite the initial promise of cancer therapies targeted against the epidermal growth factor receptor (EGFR), tumors treated with these agents eventually develop resistance. In this Review, the authors outline the complex mechanisms by which tumors become resistant to EGFR-targeted drugs and antibodies and offer insights into new strategies that might be employed to circumvent therapeutic resistance.
引用
收藏
页码：1389 / 1400
页数：11
相关论文
共 50 条
  • [21] Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer
    Spano, Jean Philippe
    Milano, Gerard
    Vignot, Stephane
    Khayat, David
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 66 (01) : 21 - 30
  • [22] Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients
    Riera, Pau
    Rodriguez-Santiago, Benjamin
    Lasa, Adriana
    Gonzalez-Quereda, Lidia
    Martin, Berta
    Salazar, Juliana
    Sebio, Ana
    Virgili, Anna C.
    Minguillon, Jordi
    Camps, Cristina
    Surralles, Jordi
    Paez, David
    CANCERS, 2020, 12 (08) : 1 - 15
  • [23] Novel somatic genetic variants as predictors of resistance to EGFR-targeted therapies in metastatic colorectal cancer patients
    Riera, P.
    Rodriguez-Santiago, B.
    Lasa, A.
    Gonzalez-Quereda, L.
    Martin, B.
    Salazar, J.
    Sebio Garcia, A.
    Virgili Manrique, A. C.
    Surralles, J.
    Paez, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S434 - S434
  • [24] EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells
    Moeller, Yvonne
    Siegemund, Martin
    Beyes, Sven
    Herr, Ricarda
    Lecis, Daniele
    Delia, Domenico
    Kontermann, Roland
    Brummer, Tilman
    Pfizenmaier, Klaus
    Olayioye, Monilola A.
    PLOS ONE, 2014, 9 (09):
  • [25] Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond
    Delaney, Christopher
    Frank, Samuel
    Huang, R. Stephanie
    CHINESE JOURNAL OF CANCER, 2015, 34
  • [26] Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
    Chang, David Z.
    Kumar, Vikas
    Ma, Ying
    Li, Kuiyuan
    Kopetz, Scott
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2009, 2
  • [27] Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer
    Lacouture, Mario E.
    CANCER NURSING, 2007, 30 (04) : S17 - S26
  • [28] EGFR Expression and KRAS Mutation in Cholangiocarcinoma: Implication in EGFR-Targeted Therapies
    Fan, L. F.
    Datta, V.
    Riley-Portuges, A.
    Lopategui, J.
    Lin, F.
    Xu, H.
    Wang, H. L.
    LABORATORY INVESTIGATION, 2010, 90 : 354A - 354A
  • [29] EGFR-targeted therapies in the post-genomic era
    Xu, Mary Jue
    Johnson, Daniel E.
    Grandis, Jennifer R.
    CANCER AND METASTASIS REVIEWS, 2017, 36 (03) : 463 - 473
  • [30] EGFR-targeted therapies in the post-genomic era
    Mary Jue Xu
    Daniel E. Johnson
    Jennifer R. Grandis
    Cancer and Metastasis Reviews, 2017, 36 : 463 - 473
12345